The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Impact of an Electronic Cigarette on Smoking Reduction and Cessation in Schizophrenic Smokers: A Prospective 12-Month Pilot Study
Open accessAbstract
Background: Cigarette smoking is a tough addiction to break. This dependence is the most common dual diagnosis for individuals with schizophrenia. Currently three effective drugs are approved for smoking cessation: nicotine replacement therapy (NRT), varenicline and bupropion. However, some serious side effects of varenicline have been reported, including depression, suicidal thoughts, and suicide. The use of bupropion also has side effects. It should not be used by people who have epilepsy or any condition that lowers the seizure threshold, nor by people who take a specific class of drugs called monoamine oxidase inhibitors. Hence, there are pharmacodynamic reason to believe they could precipitate or exacerbate psychosis. For its capacity to deliver nicotine and provide a coping mechanism for conditioned smoking cues by replacing some of the rituals associated with smoking gestures, electronic-cigarettes may reduce nicotine withdrawal symptoms without serious side effects. Our recent work with ECs in healthy smokers not intending to quit consistently show surprisingly high success rates. We hypothesised that these positive findings could be replicated in difficult patients with schizophrenia This tool may help smokers with schizophrenia remain abstinent during their quitting attempts or to reduce cigarette consumption. Efficacy and safety of these devices in long-term smoking cessation and/or smoking reduction studies have never been investigated for this special population. Methods: In this study we monitored possible modifications in smoking habits of 14 smokers (not intending to quit) with schizophrenia experimenting with the “Categoria” e-Cigarette with a focus on smoking reduction and smoking abstinence. Study participants were invited to attend six study visits: at baseline, week-4, week-8, week-12 week-24 and week 52. Product use, number of cigarettes smoked, carbon monoxide in exhaled breath (eCO) and positive and negative symptoms of schizophrenia levels were measured at each visit. Smoking reduction and abstinence rates were calculated. Adverse events were also reviewed. Results: Sustained 50% reduction in the number of cig/day at week-52 was shown in 7/14 (50%) participants; their median of 30 cig/day decreasing significantly to 15 cig/day (p = 0.018). Sustained smoking abstinence at week-52 was observed in 2/14 (14.3%) participants. Combined sustained 50% reduction and smoking abstinence was shown in 9/14 (64.3%) participants. Nausea was observed in 2/14 (14.4%) of participants, throat irritation in 2/14 (14.4%) of participants, headache in 2/14 (14.4%) of participants , and dry cough in 4/14 (28.6%) of participants. However, these adverse events diminished substantially by week-24. Overall, one to two cartridges/day were used throughout the study. Positive and negative symptoms of schizophrenia are not increased after smoking reduction/cessation in patients using e-cigarettes. Conclusions: We have shown for the first time that the use of e-cigarette substantially decreased cigarette consumption without causing significant side effects in chronic schizophrenic patients who smoke not intending to quit. This was achieved without negative impacts on the symptoms of schizophrenia as assessed by SAPS and SANS symptoms scales.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring nicotine dependence: A review of the Fagerstrom Tolerance Questionnaire
Fagerstrom, K. O., & Schneider, N. G. (1989) · Journal of Behavioral Medicine · doi:10.1007/bf00846549 · Cited by 1,598
de Leon, J., & Diaz, F. J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.010 · Cited by 1,276
Causes of the excess mortality of schizophrenia
Brown, S., Inskip, H., & Barraclough, B. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.177.3.212 · Cited by 1,087
Evins, A. E., Mays, V. K., Rigotti, N. A., Tisdale, T., Cather, C., & Goff, D. C. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200110073920 · Cited by 191
The feasibility of smoking reduction: an update
Hughes, J. R., & Carpenter, M. J. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01174.x · Cited by 168
Wennike, P., Danielsson, T., Landfeldt, B., Westin, Å., & Tønnesen, P. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00489.x · Cited by 163
Williams, J. M., Anthenelli, R. M., Morris, C. D., Treadow, J., Thompson, J. R., Yunis, C., & George, T. P. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07522 · Cited by 162
Treatment of nicotine addiction: present therapeutic options and pipeline developments
Polosa, R., & Benowitz, N. L. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.008 · Cited by 135 · cited 1×
“Moreover, the prescribing information for bupropion and varenicline, two important first-line medications for nicotine dependence, carry a “black-box” warning highlighting an increased risk of psychiatric symptoms and suicidal ideation in patients reporting any history of psychiatric illness [12].”
BackgroundEffects of cigarette reduction on cardiovascular risk factors and subjective measures
Hatsukami, D. K., Kotlyar, M., Allen, S., Jensen, J., Li, S., Le, C., & Murphy, S. (2005) · Chest · doi:10.1378/chest.128.4.2528 · Cited by 79
Cited by
E-Cigarettes: A Scientific Review
Grana, R., Benowitz, N., & Glantz, S. A. (2014) · Circulation · doi:10.1161/circulationaha.114.007667 · Cited by 1,194
Electronic cigarettes for smoking cessation
Hartmann-Boyce, J., McRobbie, H., Bullen, C., Begh, R., Stead, L. F., & Hajek, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010216.pub3 · Cited by 1,002
Kalkhoran, S., & Glantz, S. A. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00521-4 · Cited by 895
Farsalinos, K. E., & Polosa, R. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614524430 · Cited by 594
Self-citationElectronic cigarettes for smoking cessation and reduction
McRobbie, H., Bullen, C., Hartmann-Boyce, J., & Hajek, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010216.pub2 · Cited by 551
Metadata
- Authors
- Caponnetto, P., Auditore, R., Russo, C., Cappello, G., & Polosa, R.
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2013-01-28
- Volume
- 10
- Issue
- 2
- Pages
- 446-461
- ISSN
- 1660-4601 (ISSN-L)
- OpenAlex
- W2051910719
- Cited by
- 216
- References
- 9
- FWCI
- 22.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of an Electronic Cigarette on Smoking Reduction and Cessation in Schizophrenic Smokers: A Prospective 12-Month Pilot Study. https://app.cochat.ai/papers/10.3390/ijerph10020446
- The paper
- Caponnetto, P., Auditore, R., Russo, C., Cappello, G., & Polosa, R. (2013). Impact of an Electronic Cigarette on Smoking Reduction and Cessation in Schizophrenic Smokers: A Prospective 12-Month Pilot Study. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph10020446
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.